The Drivers and Barriers to Growth in the CRO Industry
Biotechnology R&D spending reached $45.7 billion by FY2016, this represented a 12% increase from the previous financial year. This was the seventh consecutive year that biotech companies increased their cumulative R&D spending and has led to a booming CRO market, expected to nearly double in a six-year period from $34 billion in 2014 to $59.42 billion in 2020. Commensurate with this market growth and as a “knock-on” effect, there has been a notable emergence of niche or specialised CROs as well as a proliferation of mergers and acquisitions as companies attempt to solidify their position in a highly competitive industry. The key CRO players continue to maintain their service focus on recruiting, developing, and retaining top performing sites. Recent hikes in clinical development programs in the last five years has caused a disparity between the growing number of studies and that of the clinical sites willing to conduct studies. This disparity has been noted as early...